Neurocysticercosis [0.03%]
囊尾蚴病
Pratibha Singhi
Pratibha Singhi
Neurocysticercosis (NCC) is the most common cause of acquired epilepsy in developing countries. It can present variably depending on the location and stage of cysts in the nervous system, and the host immune response. The most common presen...
Maja Kojovic,Carla Cordivari,Kailash Bhatia
Maja Kojovic
Myoclonus is a sudden, brief, involuntary muscle jerk. It is caused by abrupt muscle contraction, in the case of positive myoclonus, or by sudden cessation of ongoing muscular activity, in the case of negative myoclonus (NM). Myoclonus may ...
Clare M Eddy,Hugh E Rickards,Andrea E Cavanna
Clare M Eddy
TOURETTE SYNDROME (TS) IS A CHRONIC NEURODEVELOPMENTAL DISORDER CHARACTERIZED BY TICS: repetitive, involuntary movements and vocalizations. These symptoms can have a significant impact on patients' daily functioning across many domains. Tic...
Amy W Amara,Ray L Watts,Harrison C Walker
Amy W Amara
Sleep dysfunction is a common nonmotor symptom experienced by patients with Parkinson's disease (PD). Symptoms, including excessive daytime sleepiness, sleep fragmentation, rapid eye movement (REM) sleep behavior disorder and others, can si...
Impact of exposure to interferon beta-1a on outcomes in patients with relapsing-remitting multiple sclerosis: exploratory analyses from the PRISMS long-term follow-up study [0.03%]
干扰素β-1a暴露对复发缓解型多发性硬化症患者预后的影响：PRISMS长期随访研究的事后分析
Bernard Uitdehaag,Cris Constantinescu,Peter Cornelisse et al.
Bernard Uitdehaag et al.
Objective: To explore the effects of exposure to subcutaneous (sc) interferon (IFN) beta-1a on efficacy in patients with relapsing-remitting multiple sclerosis (RRMS) enrolled in the PRISMS (Prevention of Relapses and dis...
Ozgür Yaldizli,Norman Putzki
Ozgür Yaldizli
Natalizumab reduced the rate of clinical relapse at one year by 68% and the risk of sustained progression of disability by 42-54% over 2 years in its pivotal phase III trial (AFFIRM) in relapsing-remitting multiple sclerosis (RRMS). Nataliz...
Therapeutic options for continuous dopaminergic stimulation in Parkinson's disease [0.03%]
帕金森病持续多巴胺能刺激的治疗选择
O K Sujith,Carol Lane
O K Sujith
Treatment of Parkinson's disease aims to replace dopaminergic transmission at striatal synapses. In the normal state, nigral neurons fire continuously, exposing striatal dopamine receptors to relatively constant levels of dopamine. In the d...
Primary CNS lymphoma [0.03%]
原发性中枢神经系统淋巴瘤
Uwe Schlegel
Uwe Schlegel
Primary CNS Lymphoma (PCNSL) accounts for 3% of all primary brain tumors with a median age at onset of about 62 years. In the vast majority of cases, PCNSL presents as unifocal or multifocal enhancing lesions on MRI, frequently adjacent to ...
New treatment options in status epilepticus: a critical review on intravenous levetiracetam [0.03%]
难治性癫痫持续状态的新型治疗选择——利培酮静脉注射治疗癫痫持续状态临床应用述评
Eugen Trinka,Judith Dobesberger
Eugen Trinka
The effectiveness of Levetiracetam (LEV) in the treatment of focal and generalised epilepsies is well established. LEV has a wide spectrum of action, good tolerability and a favourable pharmacokinetic profile. An injectable formulation has ...
Subcutaneous Interferon Beta-1a Has a Positive Effect on Cognitive Performance in Mildly Disabled Patients with Relapsing-Remitting Multiple Sclerosis: 2-Year Results from the COGIMUS Study [0.03%]
皮下注射干扰素β-1a对复发缓解型多发性硬化症轻度残疾患者的认知表现有积极影响：COGIMUS研究的两年结果
Francesco Patti,Maria Pia Amato,Stefano Bastianello et al.
Francesco Patti et al.
The effect of interferon (IFN) beta-1a (44 and 22 μg subcutaneously [sc] three times weekly [tiw]) on cognition in mildly disabled patients with relapsing-remitting multiple sclerosis (McDonald criteria; Expanded Disability Status Scale =4...